Home
About
Warning Letter Wednesday
Work With Me
Testimonials
Appearances
Press
Regulatory Blog
Resources
More
Asa Waldstein
Community, Compliance, Natural Health
Marketing Strategy Compliance √
Test ingredients for common adulterants
9/27/23
Small labeling issues increase warning letter risk
9/6/23
Re-review online marketing if inspected by FDA
8/16/23
Biomarkers claims elevate enforcement risk
7/26/23
Review videos for compliance concerns
7/5/23
Hashtags elevate marketing risk
6/14/23
Product names are marketing
5/24/23
Ensure ingredients are lawful for supplements
5/3/23
Re-review websites if inspected by FDA
9/20/23
Learn from warning letter enforcement
8/30/23
Test products like glycerin for adulterants
8/9/23
Kratom companies should be aware
7/19/23
Test “sketchy” products for adulterants
6/28/23
Ensure substantiation is suitable for each claim
6/7/23
Ensure weight loss products are tested for drugs
5/17/23
Re-review marketing if FDA has inspected you
4/26/23
Ensure vendors are properly qualified
9/13/23
Homeopathic products under increased scrutiny
8/23/23
Repeat warning letters can have serious consequences
8/2/23
Product formats & packaging should not appeal to children
7/12/23
Small business learning lessons
6/21/23
Comparison to drugs is high risk
5/31/23
“Arthritis” claims elevate risk
5/10/23
All claims should be substantiated
4/19/23